NCT03946553|Completed
The Dysbiosis of the Intestinal Microbiota in Individuals With Allergic Rhinitis (MICRORIN)
MICRORIN
Loading search results
MICRORIN
Sponsor study identifier
observational
51
1 country
1
Study Start
May 17, 2019
Actual (reported)Primary Completion
June 21, 2019
Actual (reported)Study Completion
June 21, 2019
Actual (reported)Allergic rhinitis (AR) is triggered by environmental allergens such as pollen and mites, and is associated with several symptoms such as itching and nasal congestion, sneezing or tearing and redness of the eyes. RA can affect patients life quality who suffer it, reducing the quality of sleep and cognitive function, causing irritability and fatigue and, consequently a decrease in work performance. Because the existing pharmacological treatments for RA are not entirely effective, it is of interest to find other means to enhance the effects of these drugs and decrease more effectively the signs and symptoms associated with RA. In this context, RA has been related to an alteration of the intestinal microbiota (MI).However, there is a need to characterize in detail the MI of individuals who suffer RA. The main objective of the present study is to characterize the MI of individuals with RA, compared with people without RA. In addition, the secondary objective is to study the association between characteristics of the MI of individuals with RA and different immunological markers.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 21, 2019
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 9, 2019
Actual (reported)May 10, 2019
Actual (reported)May 17, 2019
Actual (reported)June 21, 2019
Actual (reported)June 21, 2019
Actual (reported)Intestinal microbiota characterization
Taxonomic identification of the intestinal microbiota of the participants by sequencing the fecal DNA samples using MiSeq platform of Illumina in combination with 250/300PE.
At Day 1
Inflammatory markers in blood
At Day 1
Immunological markers in faeces
At Day 1.
Immunological markers in blood
At Day 1.
Individuals with allergic rhinitis
Individuals without allergic rhinitis
In the study will be two types of populations. A population with allergic rhinitis and a population without allergic rhinitis and that serves as control group.
Technological Centre of Nutrition and Health (Eurecat-Reus)
Reus, Tarragona, 43203, Spain
fecal samples
Rosa Solà, Dr
UTNS (Eurecat_Reus)/HUSJR. Reus, Tarragona, Spain.
51 participants (actual enrollment reported by the registry).
First Submitted
May 9, 2019
First Posted
May 10, 2019
Study Start
May 17, 2019
Actual (reported)Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis
Contact the study team to confirm eligibility.
Primary Completion
June 21, 2019
Actual (reported)Study Completion
June 21, 2019
Actual (reported)Last Updated
February 28, 2022
Record last verified: 2022-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: